Cargando…
A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients
BACKGROUND: The objective of this paper is to explore the value of a delta-radiomic model of the axillary lymph node (ALN) using dynamic contrast-enhanced (DCE) MRI for early prediction of the axillary pathological complete response (pCR) of breast cancer patients after neoadjuvant chemotherapy (NAC...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817310/ https://www.ncbi.nlm.nih.gov/pubmed/36604679 http://dx.doi.org/10.1186/s12885-022-10496-5 |
_version_ | 1784864727238705152 |
---|---|
author | Liu, Shasha Du, Siyao Gao, Si Teng, Yuee Jin, Feng Zhang, Lina |
author_facet | Liu, Shasha Du, Siyao Gao, Si Teng, Yuee Jin, Feng Zhang, Lina |
author_sort | Liu, Shasha |
collection | PubMed |
description | BACKGROUND: The objective of this paper is to explore the value of a delta-radiomic model of the axillary lymph node (ALN) using dynamic contrast-enhanced (DCE) MRI for early prediction of the axillary pathological complete response (pCR) of breast cancer patients after neoadjuvant chemotherapy (NAC). METHODS: A total of 120 patients with ALN-positive breast cancer who underwent breast MRI before and after the first cycle of NAC between October 2018 and May 2021 were prospectively included in this study. Patients were divided into a training (n = 84) and validation (n = 36) cohort based on the temporal order of their treatments. Radiomic features were extracted from the largest slice of targeted ALN on DCE-MRI at pretreatment and after one cycle of NAC, and their changes (delta-) were calculated and recorded. Logistic regression was then applied to build radiomic models using the pretreatment (pre-), first-cycle(1st-), and changes (delta-) radiomic features separately. A clinical model was also built and combined with the radiomic models. The models were evaluated by discrimination, calibration, and clinical application and compared using DeLong test. RESULTS: Among the three radiomic models, the ALN delta-radiomic model performed the best with AUCs of 0.851 (95% CI: 0.770–0.932) and 0.822 (95% CI: 0.685–0.958) in the training and validation cohorts, respectively. The clinical model yielded moderate AUCs of 0.742 (95% CI: 0.637–0.846) and 0.723 (95% CI: 0.550–0.896), respectively. After combining clinical features to the delta-radiomics model, the efficacy of the combined model (AUC = 0.932) in the training cohort was significantly higher than that of both the delta-radiomic model (Delong p = 0.017) and the clinical model (Delong p < 0.001) individually. Additionally, in the validation cohort, the combined model had the highest AUC (0.859) of any of the models we tested although this was not statistically different from any other individual model’s validation AUC. Calibration and decision curves showed a good agreement and a high clinical benefit for the combined model. CONCLUSION: This preliminary study indicates that ALN-based delta-radiomic model combined with clinical features is a promising strategy for the early prediction of downstaging ALN status after NAC. Future axillary MRI applications need to be further explored. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10496-5. |
format | Online Article Text |
id | pubmed-9817310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98173102023-01-07 A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients Liu, Shasha Du, Siyao Gao, Si Teng, Yuee Jin, Feng Zhang, Lina BMC Cancer Research BACKGROUND: The objective of this paper is to explore the value of a delta-radiomic model of the axillary lymph node (ALN) using dynamic contrast-enhanced (DCE) MRI for early prediction of the axillary pathological complete response (pCR) of breast cancer patients after neoadjuvant chemotherapy (NAC). METHODS: A total of 120 patients with ALN-positive breast cancer who underwent breast MRI before and after the first cycle of NAC between October 2018 and May 2021 were prospectively included in this study. Patients were divided into a training (n = 84) and validation (n = 36) cohort based on the temporal order of their treatments. Radiomic features were extracted from the largest slice of targeted ALN on DCE-MRI at pretreatment and after one cycle of NAC, and their changes (delta-) were calculated and recorded. Logistic regression was then applied to build radiomic models using the pretreatment (pre-), first-cycle(1st-), and changes (delta-) radiomic features separately. A clinical model was also built and combined with the radiomic models. The models were evaluated by discrimination, calibration, and clinical application and compared using DeLong test. RESULTS: Among the three radiomic models, the ALN delta-radiomic model performed the best with AUCs of 0.851 (95% CI: 0.770–0.932) and 0.822 (95% CI: 0.685–0.958) in the training and validation cohorts, respectively. The clinical model yielded moderate AUCs of 0.742 (95% CI: 0.637–0.846) and 0.723 (95% CI: 0.550–0.896), respectively. After combining clinical features to the delta-radiomics model, the efficacy of the combined model (AUC = 0.932) in the training cohort was significantly higher than that of both the delta-radiomic model (Delong p = 0.017) and the clinical model (Delong p < 0.001) individually. Additionally, in the validation cohort, the combined model had the highest AUC (0.859) of any of the models we tested although this was not statistically different from any other individual model’s validation AUC. Calibration and decision curves showed a good agreement and a high clinical benefit for the combined model. CONCLUSION: This preliminary study indicates that ALN-based delta-radiomic model combined with clinical features is a promising strategy for the early prediction of downstaging ALN status after NAC. Future axillary MRI applications need to be further explored. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10496-5. BioMed Central 2023-01-05 /pmc/articles/PMC9817310/ /pubmed/36604679 http://dx.doi.org/10.1186/s12885-022-10496-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Liu, Shasha Du, Siyao Gao, Si Teng, Yuee Jin, Feng Zhang, Lina A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients |
title | A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients |
title_full | A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients |
title_fullStr | A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients |
title_full_unstemmed | A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients |
title_short | A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients |
title_sort | delta-radiomic lymph node model using dynamic contrast enhanced mri for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817310/ https://www.ncbi.nlm.nih.gov/pubmed/36604679 http://dx.doi.org/10.1186/s12885-022-10496-5 |
work_keys_str_mv | AT liushasha adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT dusiyao adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT gaosi adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT tengyuee adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT jinfeng adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT zhanglina adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT liushasha deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT dusiyao deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT gaosi deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT tengyuee deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT jinfeng deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients AT zhanglina deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients |